Review urges new quality checks for stem cell therapies

A new review says stem cell therapies may need a new manufacturing standard: measuring whether donor cells can still manage protein stress after expansion. The authors argue this could improve safety and performance as products like Ryoncil move into routine clinical use.

Why it matters: - Stem cell therapies are moving from experimental use toward routine care, but current release tests may miss a failure mode that affects whether the cells work after transplantation. - Poor protein quality control in aged or stressed donor cells can turn therapeutic products into toxic or ineffective ones. - The issue affects multiple cell therapy and extracellular vesicle applications, including blood disorders, cardiac repair, and neurological disease.

What happened: - Researchers from the University of Manitoba and Zhujiang Hospital of Southern Medical University published a 2026 review in Regenesis Repair Rehabilitation. - The paper argues that proteostatic fitness, or a cell’s ability to preserve protein balance under stress, should become a standard quality attribute for stem cell and extracellular vesicle manufacturing. - The review focuses on neural stem cell evidence but extends the concern to mesenchymal stromal cells and other therapeutic cell products. - The article cites DOI 10.1016/j.rerere.2026.06.004.

The details: - More than 115 clinical trials involving over 1,200 patients had been approved by late 2024. - The FDA approved Ryoncil, or remestemcel-L, for children with steroid-refractory acute graft-versus-host disease. - Current GMP testing focuses on identity, viability, sterility, and genetic stability. - The review says those checks are necessary but not enough to predict how cells will handle oxidative and inflammatory stress after transplant. - During ex vivo expansion, repeated cell division can drive senescence. - Senescent cells show higher p16/p21 expression, SA-β-Gal activity, and a pro-inflammatory SASP. - In healthy mesenchymal stromal cells, HSF1 activates heat shock proteins such as Hsp70 under stress. - In senescent cells, declining HSF1 activity weakens that protective response. - The team’s earlier neural stem cell work found oxidized SOD1 accumulates during senescence and enters extracellular vesicles. - Those vesicles can spread neuronal toxicity and secondary senescence to recipient cells. - SOD1 is expressed broadly across cell types, which raises concern that the same proteotoxic mechanism could extend beyond neurodegeneration. - The review points to amyotrophic lateral sclerosis as one area of concern. - The authors propose four intervention points: choosing low-senescence sources such as iPSC-derived MSCs or young donor cells, setting quantitative senescence thresholds, profiling extracellular vesicle cargo, and sanitizing pathogenic cargo before transplantation. - The review gives an example threshold of SA-β-Gal-positive cells below 10% to 15% as a batch release criterion. - The review highlights the CT4 peptide, which reduced spinal cord SOD1 burden by more than 50% in mouse models. - In cardiac repair, MSC-derived extracellular vesicles have shown anti-apoptotic and pro-angiogenic effects, but standard release criteria do not include functional bioassays to capture donor-to-donor variation. - In ALS models, intranasal healthy MSC-derived extracellular vesicles extended survival in SOD1-G93A mice. - A recent case report also found benefit from healthy MSC-derived extracellular vesicles in a neurological setting. - Neither study characterized the proteostatic state of the parent cells. - The authors say direct validation in MSC and iPSC-derived systems is still needed before universal thresholds can be set. - Funding came from the ALS Canada/Brain Canada Foundation.

Between the lines: - The review is pushing the field from basic manufacturing checks toward functional biology. - The practical shift would be from asking whether a cell product is alive and clean to asking whether it is actually resilient enough to survive the patient environment. - That could help explain why some products pass release testing but still show uneven clinical performance. - The focus on oxidized SOD1 also suggests quality control may need to address harmful cargo inside extracellular vesicles, not just the cells themselves.

What's next: - The field will need direct testing in mesenchymal stromal cells and iPSC-derived products before proteostatic thresholds can become standard. - Future work is likely to focus on quantitative senescence assays, proteomic profiling, and pre-transplant cargo-clearing methods. - If validated, the approach could reshape batch release standards for cell therapies already moving into routine care.

The bottom line: - Stem cell therapy may need a new quality metric: not just whether cells are viable, but whether their protein-control machinery is still fit for transplant.